Skip To Main Content

Their Fight Is Our Fight

Multiple myeloma doesn’t stand still. Science and innovation can’t, either.1 
When new discoveries can transform your MM patients’ lives, Sanofi wants to provide you the information needed to guide those transformations.

Science in Multiple Myeloma

Get a 360º view and stay updated on Multiple Myeloma with content selected for you

Sort by
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

ISTH Guidelines

ISTH Guidelines

Multiple Myeloma: Elderly Patients

Multiple Myeloma: Elderly Patients

Multiple Myeloma: High Risk Cytogenetics

Multiple Myeloma: High Risk Cytogenetics

Multiple Myeloma: Renal Impairment

Multiple Myeloma: Renal Impairment

Lenalidomide Refractory Patients

Lenalidomide Refractory Patients

Multiple Myeloma: Minimal Residual Disease

Multiple Myeloma: Minimal Residual Disease

Multiple Myeloma: Chromosome 1q+ cytogenetic abnormalities

Multiple Myeloma: Chromosome 1q+ cytogenetic abnormalities

Patients Factors & Impacts

Patients Factors & Impacts

Myeloma Facts

Myeloma Facts

About MRD

About MRD

Minimal Residual Disease

Minimal Residual Disease

MAT-AE-2200366-V2-Oct-23